Affymax, (FRA:A5Y) EBIT per Share : €0.05 (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, EBIT per Share?

Affymax,'s EBIT per Share for the three months ended in Jun. 2014 was €0.14. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2014 was €0.05.

During the past 3 years, the average EBIT per Share Growth Rate was -12.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -32.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Affymax,'s EBIT per Share or its related term are showing as below:

FRA:A5Y' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 0 Med: -37.75 Max: 16.9
Current: -12.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Affymax, was 16.90% per year. The lowest was 0.00% per year. And the median was -37.75% per year.

FRA:A5Y's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.5 vs FRA:A5Y: -12.20

Affymax,'s EBIT for the three months ended in Jun. 2014 was €5.31 Mil.

Affymax, EBIT per Share Historical Data

The historical data trend for Affymax,'s EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, EBIT per Share Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

EBIT per Share

Get a 7-Day Free Trial

-2.83

-0.43

-1.40

-1.93

-0.30

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
EBIT per Share	Get a 7-Day Free Trial															0.29	-0.03	-0.03	-0.03	0.14

Affymax, EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Affymax,'s EBIT per Share for the fiscal year that ended in Dec. 2013 is calculated as

	EBIT per Share		(A: Dec. 2013 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.962	/	36.342
=	-0.30

Affymax,'s EBIT per Share for the quarter that ended in Jun. 2014 is calculated as

	EBIT per Share		(Q: Jun. 2014 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	5.306	/	37.469
=	0.14

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05

Affymax, (FRA:A5Y) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Affymax, EBIT per Share Related Terms

Thank you for viewing the detailed overview of Affymax,'s EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines